COMPANY PROFILE / CELL CULTURE TECHNOLOGY
Thermo Fisher Scientific
The industry giant that sells media and single-use kit while also making cell therapies for others
Thermo Fisher comes up whenever cell culture is discussed because it supplies, in very large quantities, the media (under the Gibco brand) and single-use bioreactors used to make antibody drugs and other biologics. Its Form 10-K for the year to December 2025 puts revenue from BioProduction, the business that serves drug production and includes cell culture, at US$3.2 billion, and states that "the increase in organic revenues in 2025 was driven by the bioproduction business". At the same time, the company has a range of instruments and reagents for cell therapy (Cell Therapy Systems, or CTS), and even runs a cGMP cell therapy manufacturing site next to a U.S. university hospital. This profile keeps the company as a whole to a minimum and concentrates on what Thermo Fisher is putting into cell culture, who it is working with and what it is aiming for.
- Thermo Fisher in 30 seconds, and where it stands in cell culture
- The logo and how the name is written
- Where the company sits in the cell culture field
- Scale (the company as a whole, in brief)
- Resources committed to cell culture
- What it has done so far
- What comes next
- What the company is aiming for in cell culture
- Map of cell culture partnerships
- Technologies, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Thermo Fisher in 30 seconds, and where it stands in cell culture
USA168 Third Avenue
CDMO (secondary)Involved in both (1) biologics production and (2) cell therapy
(Cell Therapy Systems)From cell isolation and activation to expansion and fill
and filtration businessCompleted September 2025. About US$4 billion in cash
Companies involved in cell culture fall into three broad types: contract development and manufacturing organisations (CDMOs), suppliers of tools, consumables and media, and developers of cell and regenerative therapies. Thermo Fisher is first and foremost a supplier. The 10-K says its bioproduction business focuses on "upstream cell culture, downstream purification, analytics" and "a suite of single-use solutions" Sourced. But the company also has a contract drug manufacturing (pharma services) business in a separate segment, and it has announced that it takes on clinical and commercial manufacturing of cell therapies at a cGMP facility next to a university hospital Sourced. It therefore straddles two of the three types: it may end up competing for manufacturing contracts with the very customers (drug makers and CDMOs) it sells tools to. "Cell culture" also covers two different things: (1) growing animal cells, such as CHO cells, to produce antibodies and other biologics, and (2) cell therapy, where the cells themselves are the product. Thermo Fisher sells into both.
2. The logo and how the name is written
The Thermo Fisher Scientific logo is a trademark of the company. We have not recreated it with generated imagery;
the file img/thermo_fisher_logo.svg is an image taken from the company's official website.
A note on names: the name used in statutory filings is Thermo Fisher Scientific Inc. The company trades under a number of brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon and PPD, and its cell culture media are sold as Gibco. When "Gibco" or "Patheon" appears in an article or a product catalogue, it refers to products or services from this same company. This article shortens the name to "Thermo Fisher".
https://www.thermofisher.com/3. Where the company sits in the cell culture field
We found no statement, in either the 10-K or the press releases, that the company develops or sells cell therapies as its own products. It does not belong in the right-hand column of cell and regenerative therapy developers; it is best described as selling tools and contract manufacturing to those developers Sourced.
4. Scale (the company as a whole, in brief)
Thermo Fisher is a giant whose businesses stretch from analytical instruments to diagnostics and clinical trial services. The company as a whole gets a single table here; the focus is on the figures for the businesses that touch cell culture Sourced.
| Whole company | Year to Dec 2023 | Year to Dec 2024 | Year to Dec 2025 |
|---|---|---|---|
| Revenues (US$ million) | 42,857 | 42,879 | 44,556 |
| R&D expenses (US$ million) | 1,337 | 1,390 | 1,397 |
| Employees | - | - | About 125,000 (Americas 59,000 / Asia-Pacific 22,000 / Europe, Middle East and Africa 44,000) |
The scale of the businesses that touch cell culture
Of its four segments, the 10-K places a business called BioProduction inside Life Sciences Solutions and discloses its revenue. BioProduction "provides solutions for both the production of biologics and industrial manufacturing", covering upstream cell culture (media and the like), downstream purification, analytics and single-use products. Of all the numbers the company publishes, this is the closest measure of its size in cell culture.
| Business (US$ million) | 2023 | 2024 | 2025 | Jan to Jun 2026 |
|---|---|---|---|---|
| BioProduction | 2,923 | 2,652 | 3,200 | 1,834 (prior-year period 1,416) |
| Life Sciences Solutions segment total | 9,977 | 9,631 | 10,374 | 5,450 (prior-year period 4,840) |
| (For reference) pharma services business | 6,806 | 6,685 | 7,142 | - |
Sources: "Revenues by business" in the Form 10-K for the year to December 2025, and the Form 10-Q for the quarter ended June 2026. Pharma services also includes contract work on small-molecule drugs, so it is not a cell-culture-only figure.
BioProduction revenue rose by US$548 million in 2025 (as stated in the 10-K), a growth rate of about 20.7% Our calculation. BioProduction accounts for about 30.8% of Life Sciences Solutions and about 7.2% of group revenue Our calculation (3,200 ÷ 10,374 and 3,200 ÷ 44,556). The 10-K attributes the growth to "higher demand from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation business" Sourced. Revenue in January to June 2026 was also up about 29.5% on the same period a year earlier Our calculation, but that too includes sales from the acquired filtration business, so it should be read separately from growth in cell culture itself.
BioProduction also includes downstream purification and filtration, and industrial applications; it is not revenue from "cell culture" (media and bioreactors) alone. And revenue from cell therapy products (the CTS range) is not disclosed Not yet confirmed. The 10-K for the year to December 2025 that we read gives no business-level explanation of why BioProduction revenue fell in 2024, and this article does not guess. Figures such as "X% share of the global cell culture market" are research-firm estimates, and we do not use them.
5. Resources committed to cell culture
Following our standard method, we look at four things (people, money, investments and acquisitions, and university links) and note whether each could be confirmed from primary sources.
| Resource | What primary sources confirm | Status |
|---|---|---|
| People (dedicated organisation) | There is a Senior Vice President and President, BioProduction. Press releases name heads of business units such as the "cell culture and cell therapy business", the "cell culture business" and the "single-use technologies business" | Organisation confirmed |
| People (headcount) | Headcount for BioProduction or the cell therapy business. For individual sites, the company has said the plant in Lebanon, Tennessee (near Nashville) employed about 300 people in 2022, with 1,400 new jobs planned on completion, and that the Chelmsford, Massachusetts plant will employ up to 250 | Not disclosed for the business as a whole |
| Money (R&D and capital expenditure) | Life Sciences Solutions segment R&D of US$553 million and capital expenditure of US$152 million (2025). A capacity expansion programme of more than US$650 million announced in 2021 (11 sites). Individually, US$105 million for the Lebanon plant and US$160 million for the Chelmsford plant | Confirmed at segment level. Not disclosed for BioProduction alone |
| Investments and acquisitions | Solventum's purification and filtration business (September 2025, about US$4 billion), Novasep's viral vector manufacturing business (January 2021, about €725 million), and cell sorting technology from Propel Labs (February 2021) | Confirmed |
| Universities and research institutions | A strategic cell therapy partnership with the University of California, San Francisco (UCSF) (May 2021). A cGMP manufacturing facility next to the UCSF campus opened in March 2023 | Confirmed |
| Start-up investments | No investment (corporate venture capital) in cell culture or cell therapy start-ups is mentioned in the 10-K or press releases we read. There is a collaboration (ArsenalBio) and a site set up inside an incubator (BioLabs) | Not mentioned (we do not conclude that none exists) |
In money terms the biggest item is acquisitions. For Solventum's purification and filtration business, the 10-K records cash paid of US$3,944 million, and the press release says that "for the full year 2025, the business is expected to generate approximately $750 million of revenue" Sourced. In other words, Thermo Fisher bolted on a whole business nearly a quarter the size of BioProduction's 2025 revenue (US$3.2 billion) Our calculation.
Of the 5-litre benchtop DynaDrive single-use bioreactor launched in April 2025, the company says it offers "effective scale-up with consistent design, software, and film across all sizes", from 1 to 5,000 litres. The film is described as "biobased films built on Thermo Fisher's existing Aegis film offerings" Sourced.
A single-use culture bag is a multilayer polymer film in direct contact with the culture fluid. Substances released from the film (extractables and leachables) can affect cell growth and product quality, so if the wetted material changes every time a process is scaled up, it has to be re-evaluated each time. From the materials side, using the same film from small development vessels to large production ones reads as a way of "eliminating material risk at scale-up from the start" Not yet confirmed. The press release does not disclose the film's layer structure or any extractables data.
6. What it has done so far
| When | What happened | Why it matters |
|---|---|---|
| From 2020 | Collaboration begins with ArsenalBio (a developer of CAR-T therapies for solid tumours), supporting development of a clinical-scale process involving gene editing | The start of working inside customers' efforts to build a cell therapy manufacturing process |
| January 2021 | Acquisition of Novasep's viral vector manufacturing business (Henogen S.A. in Belgium) for about €725 million. Two sites, Seneffe and Gosselies, with about 400 employees | Expands contract manufacturing in Europe of the viral vectors used in gene and cell therapy |
| February 2021 | Acquires cell sorting technology (the Bigfoot Spectral Cell Sorter) and about 40 staff from Propel Labs | Strengthens research instruments for cell separation |
| March 2021 | Announces more than US$600 million of capital investment to expand bioprocessing production capacity (through 2022, 11 sites, more than 1,500 new jobs). Raised to "more than US$650 million" in September the same year | A plan to "more than double" capacity for single-use products, media and purification resins |
| May 2021 | Strategic cell therapy partnership with UCSF. Thermo Fisher announces it will build and operate a cell therapy cGMP manufacturing and collaboration center of about 44,000 square feet in leased space on UCSF's Mission Bay campus | A model that puts a manufacturing site right next to a university hospital |
| August 2022 | Expands the dry powder media plant in Grand Island, New York (adding more than 45,000 square feet of animal-origin-free manufacturing space) | Builds redundancy into the supply of Gibco media |
| August 2022 | Opens its largest single-use technology plant in Lebanon, Tennessee (US$105 million, 400,000 square feet) | A volume production site for culture bags and fluid-transfer assemblies |
| September 2022 | Opens a purification resin plant in Chelmsford, Massachusetts (US$160 million) | Supply capacity on the downstream (purification) side |
| March 2023 | Opens the cell therapy cGMP facility next to UCSF. The company describes a network of more than 15 contract sites supporting cell and gene therapies | Capacity to make cell therapies under contract, for clinical and commercial supply, goes live |
| April 2025 | Announces an additional US$2 billion of investment in the United States over four years (US$1.5 billion of capital expenditure plus US$500 million of R&D). The same month, opens an Advanced Therapies Collaboration Center (ATxCC, 6,000 square feet) for cell therapy in Carlsbad, California | The US$2 billion is a company-wide figure; the cell culture share is not disclosed |
| September 2025 | Completes the acquisition of Solventum's purification and filtration business (about US$4 billion), which becomes part of BioProduction | Rounds out an in-house range from upstream culture to downstream filtration |
| September 2025 | Dr. Park, a South Korean viral vector CDMO, announces that it has chosen Thermo Fisher to equip its new plant (including a 1,000-litre single-use bioreactor) | An example of supplying equipment to a CDMO |
| November to December 2025 | Opens a second ATxCC in Philadelphia (inside the BioLabs incubator). In Asia, expands its bioprocess design centers in Incheon and Singapore and opens a new one in Hyderabad, India | A network of sites that gets inside customers' development stages |
| April to May 2026 | Opens a U.S. flagship bioprocess design center in Plainville, Massachusetts. Launches the CTS Compleo automated fill system and the CTS DynaXS stirred-tank single-use bioreactor for cell therapy | Expands a range of products that moves cell therapy manufacturing "from manual work to machines" |
| September 2026 | Launches a panel of media and feeds for CHO-K1 cells | Broadens its media range for antibody production |
7. What comes next
by year fiveAdjusted operating income from revenue and cost synergies (company expectation)
The 10-K frames the company's growth strategy around three pillars: "high-impact innovation", its "trusted partner status with customers" and its "unparalleled commercial engine" Sourced. On cell culture specifically, the 2025 and 2026 press releases are notably concentrated on two things: sites where process development is done together with customers (the bioprocess design centers and the ATxCCs) and equipment that automates and closes off cell therapy manufacturing.
None of the following appears in the 10-K, 10-Q or press releases we read Not yet confirmed.
Revenue targets for BioProduction or the cell therapy business; the total amount and timing of capital expenditure on cell culture (the breakdown of the US$2 billion); production capacity for media and single-use products (in litres or units); and the overall number of orders or the full customer list for contract cell therapy manufacturing. Figures of the form "the bioprocessing market is growing X% a year" usually come from research firms, and this article does not use them.
8. What the company is aiming for in cell culture
This section goes beyond what the company says directly. It sets out inferences that can be drawn from primary sources, each with its basis.
| What can be read | Primary evidence behind it | Category |
|---|---|---|
| It wants to be a supplier of the whole workflow, providing everything from culture to purification and analytics from one company | The press release for the Plainville design center describes an "end-to-end bioproduction workflow" covering "media, cell line development, single-use systems, chromatography, filtration, purification and analytics". The Solventum filtration acquisition is likewise described as spanning "upstream and downstream workflows" | Inference |
| In cell therapy, it aims to capture the shift from flat, manual culture to stirred tanks and automation with its own products | The CTS DynaXS release cites the pressure on manufacturers "to transition from static culture systems to scalable, automation-ready platforms", and the CTS Compleo release calls manual fill and finish one of the biggest bottlenecks | Inference |
| It puts weight on getting in early in customers' development and having its products built into their manufacturing processes | The ATxCC offers access even to technologies not yet on the market. It has supported ArsenalBio's process development since 2020, and CTS products are used in ArsenalBio's clinical manufacturing | Inference |
| In cell therapy it works on both fronts: selling products and taking on contract manufacturing | It has announced that it provides clinical and commercial cGMP manufacturing services at the facility next to UCSF, and describes more than 15 contract sites | Sourced |
| It appears to have no plans to develop and sell cell therapies of its own | Neither the 10-K nor the press releases mention developing its own cell therapy products. The language is consistently that of a company supporting its customers (the developers) | Inference |
The press release for the Carlsbad ATxCC, opened in April 2025, says cell therapy developers gain access to Thermo Fisher equipment and analytical solutions "even before these technologies are available to the broader market" Sourced. In cell therapy, changing a manufacturing process after approval from the one used in clinical trials means repeating the work of proving comparability, which is a heavy burden. Equipment and reagents adopted early in development therefore tend to stay in use all the way to commercial production. The ArsenalBio case (collaboration from 2020, followed by CTS products being adopted in clinical manufacturing) is the company itself publicising exactly this pattern. Our reading is that the purpose of Thermo Fisher's investment in this network of sites is to secure "adoption during development, and hence a steady stream of consumables sales in future" Not yet confirmed.
9. Map of cell culture partnerships
The map shows a clear division of roles: with universities and cell therapy developers, Thermo Fisher "builds processes together"; with CDMOs, it "sells equipment"; and it grows by acquisition. The UCSF relationship in particular is different in kind from ordinary joint research: Thermo Fisher built the facility for the university, runs it itself, and also takes on manufacturing for customers other than UCSF Sourced.
10. Technologies, products and services
| Area | Main products and services (as described in press releases and the 10-K) | (1) Biologics / (2) Cell therapy |
|---|---|---|
| Media | Gibco-brand media and feeds. In September 2026 it launched a panel of chemically defined, animal-origin-free media and feeds for CHO-K1 cells (liquid and powder) | (1) |
| Bioreactors | Single-use bioreactors (HyPerforma, DynaDrive). DynaDrive uses the same design and film from 1 to 5,000 litres | (1) (also used for viral vector production) |
| Single-use components | Culture bags (BioProcess Containers) and fluid-transfer assemblies, made at the Lebanon plant | (1) (2) |
| Purification and filtration | POROS purification resins, and bioprocess filtration products from the former Solventum business | (1) |
| Cell therapy instruments and reagents (CTS) | CTS Xenon (electroporation), CTS Rotea (cell processing by counterflow centrifugation), CTS DynaXS (stirred-tank single-use bioreactor, May 2026), CTS Compleo (automated, functionally closed fill system, April 2026) | (2) |
| Contract development and manufacturing | Development and manufacturing of small- and large-molecule drugs for other companies through the pharma services business. Clinical and commercial cell therapy manufacturing at the facility next to UCSF and elsewhere. Contract viral vector manufacturing at the Belgian sites and elsewhere | (1) (2) |
| Process development support sites | Bioprocess design centers (Plainville, Incheon, Singapore, Hyderabad) and ATxCCs (Carlsbad, Philadelphia) | (1) (2) |
For the CHO-K1 media launched in September 2026, the company reports that "in a 14-day fed-batch study", selected panel combinations showed "up to 73% higher titer" and "up to 202% higher peak viable cell density" than the benchmark products tested Sourced. These are, however, the company's own tests, and the benchmark products are not named.
The press release on the Grand Island expansion says the extra animal-origin-free (AOF) capacity includes manufacturing of dry powder media in the company's Advanced Granulation Technology (AGT) format Sourced. Culture media are powders blended from dozens of amino acids, vitamins, inorganic salts and sugars; left as fine powder, they tend to form lumps, raise dust and segregate when dissolved. Granulating them to a uniform particle size is, in powder-engineering terms, a way of improving flowability and solubility, and it is a materials-side answer to the need to "make a liquid of identical composition, quickly, every time" for cultures of thousands of litres. The press release does not disclose AGT's particle size or process conditions Not yet confirmed. Our explainer on cell culture media also covers when powder and liquid media are used.
11. The risks this company carries
| Risk | Substance | Category |
|---|---|---|
| Dependence on customers' capital and research spending | The 10-K states plainly that "demand for some of our products depends on capital spending policies of our customers and on government funding policies", covering drug and biotech companies, universities and government bodies | Sourced |
| BioProduction revenue swings from year to year | US$2.92 billion in 2023, US$2.65 billion in 2024, US$3.20 billion in 2025: in one year revenue fell by almost 10% | Sourced |
| Integrating acquired businesses | The Solventum filtration business was excluded from the assessment of internal control at the end of 2025 (because it had only just been acquired). The synergy figure of about US$125 million is only a company expectation | Sourced |
| Tariffs and China | The 10-K lists tariffs between the United States and other countries, and Chinese rules favouring local suppliers, as risks. It says revenue in China fell in 2025 | Sourced |
| Reliance on particular suppliers | It says that, for reasons of quality assurance and regulation, some materials and components are sourced "from a single supplier or a limited number of suppliers" | Sourced |
| Competing with its own customers | CDMOs are among the customers for its media and equipment, yet its pharma services business competes with them for orders as a CDMO itself. That could give CDMO customers a reason to switch suppliers | Inference |
| The size of the cell therapy business is invisible | Revenue from CTS products and contract cell therapy manufacturing is not disclosed, so the return on investment cannot be checked from outside | Not yet confirmed |
12. Glossary
- CHO cells
- A cell line derived from Chinese hamster ovary. The most widely used cells for producing antibody drugs. CHO-K1 is one lineage.
- Media and feeds
- The liquids (or dissolved powders) that nourish cells. A feed is a concentrated nutrient solution added during culture. See our explainer on cell culture media for more.
- Fed-batch culture
- A culture method in which feed is added during the run and everything is harvested at once after a set period.
- Single-use bioreactor
- A culture vessel that uses a disposable plastic bag, removing the need for cleaning and sterilisation. See also our explainer on single-use systems.
- CDMO
- A company that develops and manufactures drugs under contract for other companies. See our explainer on CDMOs for more.
- cGMP
- current Good Manufacturing Practice: the standards for manufacturing control and quality control of medicines.
- CAR-T cell therapy
- A treatment in which a patient's T cells are genetically modified to attack cancer cells and then returned to the body.
- Viral vector
- A virus modified to carry genes into cells. Used in gene therapy and in making some cell therapies.
- Animal origin-free (AOF)
- Media made without animal-derived ingredients such as serum. Reduces lot-to-lot variation and the risk of infectious agents.
- Form 10-K / 10-Q
- The annual and quarterly reports that U.S.-listed companies file with the SEC.
13. References
- Thermo Fisher Scientific Form 10-K for the fiscal year ended December 31, 2025 (filed with the U.S. SEC on 26 February 2026). Business and segment descriptions, revenues, revenues by business (including BioProduction), R&D expenses, capital expenditure by segment, headcount, the purchase price of the Solventum filtration business, risk factors and restructuring charges. https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm
- Thermo Fisher Scientific Form 10-Q for the quarterly period ended June 27, 2026 (filed with the U.S. SEC on 31 July 2026). Revenues by business for January to June 2026, and the reasons for BioProduction's revenue growth. https://www.sec.gov/Archives/edgar/data/97745/000009774526000144/tmo-20260627.htm
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Launches Gibco CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development" (23 September 2026). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Launches-Gibco-CHO-K1-Catalog-Panel-Media-and-Feed-to-Accelerate-Biologics-Development/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing" (4 May 2026). CTS DynaXS. https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Unveils-an-Integrated-Platform-to-Advance-Scalable-Cell-Therapy-Manufacturing/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Introduces the Gibco CTS Compleo Fill and Finish System to Help Streamline Cell Therapy Manufacturing" (2 April 2026). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Introduces-the-Gibco-CTS-Compleo-Fill-and-Finish-System-to-Help-Streamline-Cell-Therapy-Manufacturing/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies" (28 April 2026). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Opens-U-S--Flagship-Bioprocess-Design-Center-to-Accelerate-the-Delivery-of-Life-changing-Therapies/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers" (2 December 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Deepens-Investment-in-Asias-Biopharma-Ecosystem-with-Expansion-of-Bioprocess-Design-Centers/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development" (18 November 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Opens-East-Coast-Collaboration-Center-at-BioLabs-for-Advanced-Therapeutics-to-Help-Accelerate-Cell-and-Gene-Therapy-Development/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development" (17 April 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Opens-Advanced-Therapies-Collaboration-Center-in-Greater-San-Diego-to-Help-Accelerate-Cell-Therapy-Development/default.aspx
- Thermo Fisher Scientific Press release, "Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility" (24 September 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Dr--Park-CDMO-Selects-Thermo-Fisher-Scientific-to-Equip-New-Viral-Vector-Manufacturing-Facility/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Completes Acquisition of Solventum’s Purification and Filtration Business" (2 September 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Completes-Acquisition-of-Solventums-Purification-and-Filtration-Business/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers’ Manufacturing" (24 April 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Invests-to-Enhance-U-S--Innovation-and-Support-Customers-Manufacturing/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster" (14 April 2025). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-Introduces-the-5L-DynaDrive-Single-Use-Bioreactor-to-Simplify-and-Accelerate-Process-Development-and-Help-Bring-Therapies-to-Market-Faster/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies" (27 March 2023). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific and University of California San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center" (19 May 2021). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2021/Thermo-Fisher-Scientific-and-University-of-California-San-Francisco-to-Open-Cell-Therapy-cGMP-Manufacturing-and-Collaboration-Center-05-19-2021/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies" (29 March 2023). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-and-Arsenal-Biosciences-Collaborate-to-Support-Clinical-Manufacturing-of-Autologous-T-Cell-Therapies/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep" (15 January 2021). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2021/Thermo-Fisher-Scientific-Acquires-Viral-Vector-Manufacturing-Business-from-Novasep-01-15-2021/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs" (17 February 2021). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2021/Thermo-Fisher-Scientific-Acquires-Leading-Cell-Sorting-Technology-from-Propel-Labs-02-17-2021/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Investments Support Rapidly Increasing Bioprocessing Production" (10 March 2021). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2021/Thermo-Fisher-Scientific-Investments-Support-Rapidly-Increasing-Bioprocessing-Production-03-10-2021/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific to Further Expand Global Network of Single Use Technology Manufacturing Sites" (8 September 2021). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2021/Thermo-Fisher-Scientific-to-Further-Expand-Global-Network-of-Single-Use-Technology-Manufacturing-Sites-09-08-2021/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific’s Largest Single-Use Technology Manufacturing Site Opens in Greater Nashville" (22 August 2022). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2022/Thermo-Fisher-Scientifics-Largest-Single-Use-Technology-Manufacturing-Site-Opens-in-Greater-Nashville/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Invests $160 Million to Expand Bioproduction Capacity in Greater Boston" (20 September 2022). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2022/-Thermo-Fisher-Scientific-Invests-160-Million-to-Expand-Bioproduction-Capacity-in-Greater-Boston/default.aspx
- Thermo Fisher Scientific Press release, "Thermo Fisher Scientific Expands Cell Culture Media Manufacturing Site in Grand Island New York" (4 August 2022). https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2022/Thermo-Fisher-Scientific-Expands-Cell-Culture-Media-Manufacturing-Site-in-Grand-Island-New-York/default.aspx
- Thermo Fisher Scientific Official website (source of the logo image). https://www.thermofisher.com/
14. Claim-to-source audit
Last updated 24 September 2026 / Troy Technical
Every figure in this article comes from statutory filings Thermo Fisher Scientific has made with the U.S. Securities and Exchange Commission (SEC) and from press releases in the company's official newsroom. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of primary sources, not statements made by the company.